VIPoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Aditya Ganti (talk | contribs) |
Aditya Ganti (talk | contribs) |
||
| Line 5: | Line 5: | ||
Other imaging studies for VIPoma include [[somatostatin]] receptor [[Nuclear medicine|scintigraphy]] and [[Positron emission tomography|PET]] scan using radiolabeled somatostatin analogs. | Other imaging studies for VIPoma include [[somatostatin]] receptor [[Nuclear medicine|scintigraphy]] and [[Positron emission tomography|PET]] scan using radiolabeled somatostatin analogs. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
[[Somatostatin]] receptor [[scintigraphy]] (Octreoscan) is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. Nearly 80-90% of all VIPoma are somatostatin receptor positive.<ref name="pmid24785507">{{cite journal| author=Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T| title=Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. | journal=Hematol Oncol Stem Cell Ther | year= 2014 | volume= 7 | issue= 3 | pages= 109-15 | pmid=24785507 | doi=10.1016/j.hemonc.2014.03.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24785507 }}</ref><ref name="MüllerKupka2012">{{cite journal|last1=Müller|first1=Sven|last2=Kupka|first2=Susan|last3=Königsrainer|first3=Ingmar|last4=Northoff|first4=Hinnak|last5=Sotlar|first5=Karl|last6=Bock|first6=Thomas|last7=Kandolf|first7=Reinhard|last8=Traub|first8=Frank|last9=Königsrainer|first9=Alfred|last10=Zieker|first10=Derek|title=MSH2 and CXCR4 involvement in malignant VIPoma|journal=World Journal of Surgical Oncology|volume=10|issue=1|year=2012|pages=264|issn=1477-7819|doi=10.1186/1477-7819-10-264}}</ref> | * [[Somatostatin]] receptor [[scintigraphy]] (Octreoscan) is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. | ||
* Nearly 80-90% of all VIPoma are somatostatin receptor positive.<ref name="pmid24785507">{{cite journal| author=Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T| title=Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male. | journal=Hematol Oncol Stem Cell Ther | year= 2014 | volume= 7 | issue= 3 | pages= 109-15 | pmid=24785507 | doi=10.1016/j.hemonc.2014.03.002 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24785507 }}</ref><ref name="MüllerKupka2012">{{cite journal|last1=Müller|first1=Sven|last2=Kupka|first2=Susan|last3=Königsrainer|first3=Ingmar|last4=Northoff|first4=Hinnak|last5=Sotlar|first5=Karl|last6=Bock|first6=Thomas|last7=Kandolf|first7=Reinhard|last8=Traub|first8=Frank|last9=Königsrainer|first9=Alfred|last10=Zieker|first10=Derek|title=MSH2 and CXCR4 involvement in malignant VIPoma|journal=World Journal of Surgical Oncology|volume=10|issue=1|year=2012|pages=264|issn=1477-7819|doi=10.1186/1477-7819-10-264}}</ref> | |||
[[Image:PET CT.jpg|thumb|center|400px|PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image)]] | [[Image:PET CT.jpg|thumb|center|400px|PET-CT with MBq 68-Gallium-DOTATOC showing enhancement of multiple lesions in the right lobe of the liver (upper image) and a slight enhancement in the caudal pancreas (lower image)]] | ||
Revision as of 19:45, 19 January 2018
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of VIPoma other imaging findings |
|
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3]
Overview
Other imaging studies for VIPoma include somatostatin receptor scintigraphy and PET scan using radiolabeled somatostatin analogs.
Other Imaging Findings
- Somatostatin receptor scintigraphy (Octreoscan) is used to localise the tumor, which is usually metastatic at presentation.
- Nearly 80-90% of all VIPoma are somatostatin receptor positive.[1][2]
References
- ↑ Abu-Zaid A, Azzam A, Abudan Z, Algouhi A, Almana H, Amin T (2014). "Sporadic pancreatic vasoactive intestinal peptide-producing tumor (VIPoma) in a 47-year-old male". Hematol Oncol Stem Cell Ther. 7 (3): 109–15. doi:10.1016/j.hemonc.2014.03.002. PMID 24785507.
- ↑ Müller, Sven; Kupka, Susan; Königsrainer, Ingmar; Northoff, Hinnak; Sotlar, Karl; Bock, Thomas; Kandolf, Reinhard; Traub, Frank; Königsrainer, Alfred; Zieker, Derek (2012). "MSH2 and CXCR4 involvement in malignant VIPoma". World Journal of Surgical Oncology. 10 (1): 264. doi:10.1186/1477-7819-10-264. ISSN 1477-7819.